← All diseases
Rare and hereditary disorders
Epidermolysis bullosa
Would you like to receive a message when there is new research about Epidermolysis bullosa? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, one sentence appears above each publication explaining what was investigated — and you'll receive a notification as soon as new research on Epidermolysis bullosa is available. View what Premium costs.
Publications and studies (1208)
- Efficacy of Oral Cicaglocal for Wound Healing and Pruritus Alleviation in Patients with Epidermolysis Bullosa: A Single-Arm Clinical Trial. (2026/04/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Tsukamurella pulmonis bacteremia in a young patient with epidermolysis bullosa: A case report. (2026/04/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case Report: Two neonatal cases of genetically confirmed junctional epidermolysis bullosa in a tertiary care center. (2026/03/23) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A Novel Nasal Continuous Positive Airway Pressure-Assisted Approach for Airway Management in a Patient With Dystrophic Epidermolysis Bullosa: A Case Report. (2026/03/14) ♡
- Clinical and molecular spectrum of inherited epidermolysis bullosa in a Thai cohort: A 12-year retrospective study. (2026/03/07) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Long-term survival in severe epidermolysis bullosa simplex with the potentially fatal KRT5 p.Glu477Lys variant. (2026/03/06) ♡
- Systemic inflammation in recessive dystrophic epidermolysis bullosa: a five-year longitudinal study. (2026/03/05) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Crusted scabies in patients with recessive dystrophic epidermolysis bullosa. (2026/03/02) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Laryngo-Onycho-Cutaneous Syndrome Managed With Thalidomide. (2026/03/01) ♡
- Reflectance confocal microscopy analysis of epidermolysis bullosa nevi - A cross-sectional study. (2026/03/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Whole-Exome Sequencing Identified a Novel Mutation in an Iranian Patient with Epidermolysis Bullosa. (2026/03/01) ♡
- Multidisciplinary Management of Epidermolysis Bullosa. (2026/02/24) ♡
- Nailed it? A diagnostic puzzle in an infant. (2026/02/13) ♡
- A novel variant c.A527G in ITGB4 leads to autosomal dominant epidermolysis bullosa in China. (2026/02/05) ♡
- Prime editing as a promising therapeutic strategy for junctional epidermolysis bullosa. (2026/02/04) ♡
- Positive predictive values of enzyme-linked immunosorbent assay (ELISA) for antienvoplakin and anticollagen VII antibodies: Results from 4 centers from Spain. (2026/02/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Technical Challenges When Performing Ultrasound-Guided Peripheral Intravenous Placement in Children. (2026/02/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Epidermolysis Bullosa Acquisita With Extensive Esophageal Erosions. (2026/02/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Tissue-Selective Effects of PLEC Isoform Deficiency: Insights From A Muscle Only Phenotype. (2026/02/01) ♡
- Dominant Dystrophic Epidermolysis Bullosa with COL7A1 Variant Confirmed by Whole-Exome Sequencing in a Chinese Family and Genotype-Phenotype Correlation Analysis. (2026/02/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Epidermolysis Bullosa Related to the KLHL24 Gene: A Rare Pediatric Manifestation of Arrhythmogenic Cardiomyopathy. (2026/01/14) ♡
- Zinc as a Biomarker of Nutritional Status and Clinical Burden in Recessive Dystrophic Epidermolysis Bullosa: Implications for Preventive Monitoring. (2026/01/12) ♡
- Oral Rehabilitation with Dental Implants in Patients with Epidermolysis Bullosa: A Scoping Review. (2026/01/09) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case report: Epidermolysis bullosa acquisita following dipeptidyl peptidase-4 inhibitor therapy and complicated by immune thrombocytopenic purpura. (2026/01/05) ♡
- Spectrum mining of immune checkpoint inhibitor-related cutaneous toxicities and analysis of associated factors based on FAERS. (2026/01/02) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Off-Label Use of Double-Dose Beremagene Geperpavec (B-VEC) in the Treatment of Recessive Dystrophic Epidermolysis Bullosa: A Promising Clinical Case. (2026/01/01) ♡
- Umbilical Cord Blood Transplantation Provides an Alternative for Patients With Chronic Granulomatous Disease Lacking HLA-Matched Donors: A PIDTC Report. (2026/01/01) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. A systematic review of therapeutic and paradoxical roles of tumor necrosis factor α inhibitors in autoimmune blistering diseases. (2026/01/01) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex (2026-08-10) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds (2026-08-06) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa (2026-07-23) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB (2026-07-17) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Curcumin-Based Photodynamic Therapy in Epidermolysis Bullosa: Wound Healing, Quality of Life, and Salivary Biomarkers (2026-07-16) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting (2026-07-14) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) (2026-07-09) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Treatment of Dysphagia in Patients With Dystrophic Epidermolysis Bullosa With Budesonide: a Retrospective Bicentric Study Nice - Paris St Louis / Necker (EBUDE Study) (2026-07-06) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Emerging Indications for Hyperbaric Oxygen Treatment (2026-07-06) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study (2026-05-20) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Impact of Complex Care Training of Hereditary Epidermolysis Bullosa on Caregiver Burden (FIREB) (2026-05-06) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART) (2026-05-05) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa (2026-05-05) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders (2026-05-01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa (2026-04-24) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin (2026-04-20) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa (2026-03-19) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa (2026-03-19) ♡
- Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment (2026-03-18) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (2026-03-18) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Evaluation of D-Fi for the Treatment of Wounds Due to DEB (2026-03-13) ♡
- Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa (2026-03-12) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.